Abstract
The increased development and availability of therapeutic proteins (TP) requires a greater understanding of drug-drug interactions (DDI) in a poly-pharmacy environment. Medications that are likely co-administered in various patient populations have to be considered in the context of direct pharmacokinetic properties of co-administered drugs as well as indirect effects due to disease modification. Anticipating and managing drug-drug interactions are an important part of the clinical development of both small and large molecules. Animal models may provide useful information in this regard with respect to human translatability. However, very limited work has been done to better understand the value of animal models for predicting the potential for TP DDI. Potential DDI mechanisms of TPs, with the exception of cytokine-mediated alteration of drug metabolizing enzymes and transporters, are less well known. This review discusses the potential value and specific challenges in the use of animal models for TP DDI evaluation.
Keywords: Animal, biotherapeutic, drug-drug interaction, Models, Interaction, pathophysiology, clinical DDI, Ab-receptor, drug metabolizing enzymes, metabolizing enzyme, translation.
Current Drug Metabolism
Title:Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics
Volume: 13 Issue: 7
Author(s): Eugenia Kraynov, Martin E. Dowty, Odette Odette A. Fahmi and Owen Fields
Affiliation:
Keywords: Animal, biotherapeutic, drug-drug interaction, Models, Interaction, pathophysiology, clinical DDI, Ab-receptor, drug metabolizing enzymes, metabolizing enzyme, translation.
Abstract: The increased development and availability of therapeutic proteins (TP) requires a greater understanding of drug-drug interactions (DDI) in a poly-pharmacy environment. Medications that are likely co-administered in various patient populations have to be considered in the context of direct pharmacokinetic properties of co-administered drugs as well as indirect effects due to disease modification. Anticipating and managing drug-drug interactions are an important part of the clinical development of both small and large molecules. Animal models may provide useful information in this regard with respect to human translatability. However, very limited work has been done to better understand the value of animal models for predicting the potential for TP DDI. Potential DDI mechanisms of TPs, with the exception of cytokine-mediated alteration of drug metabolizing enzymes and transporters, are less well known. This review discusses the potential value and specific challenges in the use of animal models for TP DDI evaluation.
Export Options
About this article
Cite this article as:
Kraynov Eugenia, E. Dowty Martin, Odette A. Fahmi Odette and Fields Owen, Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics, Current Drug Metabolism 2012; 13 (7) . https://dx.doi.org/10.2174/138920012802138705
DOI https://dx.doi.org/10.2174/138920012802138705 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Physicochemical Interaction Study of Non-Steroidal Anti-Inflammatory Drugs with Dimyristoylphosphatidylethanolamine Liposomes
Letters in Drug Design & Discovery Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Review on Novel Carrier System: Liposomes and Proliposomes
Drug Delivery Letters An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings
Current Pediatric Reviews Biomaterial Scaffolds for Mesenchymal Stem Cell Based Therapy Aimed at Tissue Engineering Application for Osteoarthritis
Recent Patents on Nanomedicine Mechanisms of Liver Injury: An Overview
Current Molecular Medicine Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review
Current Pharmaceutical Biotechnology Gene Therapy Strategies in Prostate Cancer
Current Gene Therapy Synthesis and Anticancer Properties of ‘<i>Azole</i>’ Based Chemotherapeutics as Emerging Chemical Moieties: A Comprehensive Review
Current Organic Chemistry Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
Current Cancer Therapy Reviews Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms
Current Molecular Medicine Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry